Option Care Health Inc

Option Care Health Inc(OPCH)股票分析

$31.200

-0.019 (-0.06%)收盘时

Loading chart…
最高
31.350
开盘
31.240
成交量加权均价
31.24
成交量
2.85M
市值
4.86B
最低
31.175
成交额
88.95M
企业价值/息税折旧摊销前利润(TTM)
13.29

Option Care Health, Inc. is an independent provider of home and alternate site infusion services. Its infusion services include the clinical management of infusion therapy, nursing support and care coordination. It provides a therapy portfolio through its network of over 87 full-service pharmacies and 109 stand-alone ambulatory infusion suites. It administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women's health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient's condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement.

AI 分析 of Option Care Health Inc (OPCH)

持有

Option Care Health Inc is currently a hold. The stock is trading at $31.20, which is very close to the acquisition price of $32.05, indicating limited upside potential. The RSI is at 93.037, suggesting the stock is overbought, which may lead to a price correction. Additionally, the forward P/E ratio is 11.22, which is attractive, but the recent downgrades from multiple analysts indicate caution. The main risk is the potential for the acquisition to face regulatory hurdles, which could impact the stock negatively if the deal does not go through.

估值指标

Option Care Health Inc(OPCH)当前预期市盈率为 11.22,5 年平均预期市盈率为 24.85。

预期市盈率

低估
5 年均值 P/E
24.85
当前P/E
11.22
高估
31.75
低估
17.94

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
14.10
当前EV/EBITDA
13.29
高估
17.21
低估
10.99

预期市销率

低估
5 年均值 P/S
1.06
当前P/S
0.76
高估
1.32
低估
0.79

Alphio AI 对 OPCH 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%OPCH

$38.45

情景价格

基

基准

基准 · 50%OPCH

$31.36

情景价格

悲

悲观

悲观 · 25%OPCH

$30.06

情景价格

持有 OPCH 的大户

S

Southpoint Capital Advisors LP

+ 持有OPCH

+3.71%

3个月收益率

S

Staley Capital Advisers, Inc.

+ 持有OPCH

+2.00%

3个月收益率

D

Durable Capital Partners, LP

+ 持有OPCH

-5.68%

3个月收益率

事件时间线

2026-10-07 (ET)

08:00:00

Barrington Analyst Downgrades Option Care Health to Market Perform

2026-10-06 (ET)

16:30:00

McKesson and CD&R Agree to Acquire Option Care Health for $32.05 per Share

12:30:00

Option Care Health Shares Rise 32.9% to $31.05

12:00:00

Major Averages Rise for Second Day Amid Treasury Yield Retreat

10:30:00

Option Care Health Stock Rises 32.9% to $31.05

资讯

OPCH 常见问题 —— 由 Alphio AI 解答

Option Care Health, Inc. is an independent provider of home and alternate site infusion services. Its infusion services include the clinical management of infusion therapy, nursing support and care coordination. It provides a therapy portfolio through its network of over 87 full-service pharmacies and 109 stand-alone ambulatory infusion suites. It administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women's health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient's condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement. It operates in the Healthcare sector (SERVICES-HOME HEALTH CARE SERVICES industry).

Option Care Health Inc is currently a hold. The stock is trading at $31.20, which is very close to the acquisition price of $32.05, indicating limited upside potential. The RSI is at 93.037, suggesting the stock is overbought, which may lead to a price correction. Additionally, the forward P/E ratio is 11.22, which is attractive, but the recent downgrades from multiple analysts indicate caution. The main risk is the potential for the acquisition to face regulatory hurdles, which could impact the stock negatively if the deal does not go through.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易